About Arch Therapeutics
Arch Therapeutics is a company based in Natick (United States) founded in 2006.. Arch Therapeutics has raised $320 thousand across 13 funding rounds. Arch Therapeutics offers products and services including AC5 Advanced Wound System, AC5 Topical Hemostat, and AC5-G. Arch Therapeutics operates in a competitive market with competitors including Abyrx, Biom'Up, Prytime Medical Devices, Endomedix and United Health Products, among others.
- Headquarter Natick, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Arch Therapeutics Inc
-
Annual Revenue
$75.72 K383.8as on Sep 30, 2023
-
Net Profit
$-6.98 M-32.35as on Sep 30, 2023
-
EBITDA
$-5.04 M11.62as on Sep 30, 2023
-
Total Equity Funding
$320 K (USD)
in 13 rounds
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Arch Therapeutics
Arch Therapeutics is a publicly listed company on the OTC with ticker symbol ARTHQ in USA, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Arch Therapeutics
Arch Therapeutics offers a comprehensive portfolio of products and services, including AC5 Advanced Wound System, AC5 Topical Hemostat, and AC5-G. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Self-assembling technology for managing wounds in surgery and trauma.
Product to control bleeding during medical procedures.
Agent for gastrointestinal bleeding and submucosal lifting.
Unlock access to complete
Unlock access to complete
Funding Insights of Arch Therapeutics
Arch Therapeutics has successfully raised a total of $320K across 13 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Last Round
-
First Round
First Round
(01 Jun 2007)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2023 | Amount | Post-IPO - Arch Therapeutics | Valuation |
investors |
|
| Jul, 2022 | Amount | Post-IPO - Arch Therapeutics | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Arch Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Arch Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Arch Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Arch Therapeutics Comparisons
Competitors of Arch Therapeutics
Arch Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abyrx, Biom'Up, Prytime Medical Devices, Endomedix and United Health Products, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Hemostatic bone putty is developed for surgical bone bleeding control.
|
|
| domain | founded_year | HQ Location |
Hemostatic products for surgical applications are developed using collagen-based materials.
|
|
| domain | founded_year | HQ Location |
Developer of minimally invasive large vessel occludes for hemorrhage control in trauma patients
|
|
| domain | founded_year | HQ Location |
Hydrogel solutions for surgery and wound care are developed.
|
|
| domain | founded_year | HQ Location |
Medical device for hemostasis during surgical procedures is provided.
|
|
| domain | founded_year | HQ Location |
Absorbable surgical sealants and hemostats are developed for leakage prevention.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Arch Therapeutics
Frequently Asked Questions about Arch Therapeutics
When was Arch Therapeutics founded?
Arch Therapeutics was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Where is Arch Therapeutics located?
Arch Therapeutics is headquartered in Natick, United States. It is registered at Natick, Massachusetts, United States.
Is Arch Therapeutics a funded company?
Arch Therapeutics is a funded company, having raised a total of $320K across 13 funding rounds to date. The company's 1st funding round was a Post-IPO of $6.9M, raised on Jun 01, 2007.
What is the annual revenue of Arch Therapeutics?
Annual revenue of Arch Therapeutics is $75.72K as on Sep 30, 2023.
What does Arch Therapeutics do?
Arch Therapeutics was founded in 2006 and is headquartered in Natick, United States. Operations center on biotechnology, with development of a synthetic peptide-based hemostatic device known as AC5 for use in minimally invasive and open surgical procedures. The transparent, biocompatible material is applied to achieve rapid bleeding control and fluid leakage prevention, particularly in irregular wound sites. As of January 2016, human trials had not been conducted.
Who are the top competitors of Arch Therapeutics?
Arch Therapeutics's top competitors include Prytime Medical Devices, Biom'Up and United Health Products.
What products or services does Arch Therapeutics offer?
Arch Therapeutics offers AC5 Advanced Wound System, AC5 Topical Hemostat, and AC5-G.
Is Arch Therapeutics publicly traded?
Yes, Arch Therapeutics is publicly traded on OTC under the ticker symbol ARTHQ.
What is Arch Therapeutics's ticker symbol?
The ticker symbol of Arch Therapeutics is ARTHQ on OTC.